Olaparib tablet monotherapy yielded improved progression-free survival compared with standard-of-care chemotherapy among women with HER2-negative metastatic breast cancer and a germline BRCA mutation, according to results of a phase III trial (Abstract LBA4). Mark E. Robson, MD, of Memorial Sloan Kettering Cancer Center, presented the results of the Olympiad trial during the Plenary Session held...
Pro zobrazení tohoto obsahu je třeba být přihlášen.